SPHK1 — Sphingosine Kinase 1

Migration, Crosslink

📖

SPHK1 — Sphingosine Kinase 1

active

wiki page Created: 2026-04-02T07:19:26 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-sphk1

📖 Wiki Page

gene1441 wordssynced 2026-04-02

SPHK1 — Sphingosine Kinase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPHK1 — Sphingosine Kinase 1</th>
</tr>
<tr> [@duran2020]
<td class="label">Symbol</td> [@gulbins2013]
<td><strong>SPHK1</strong></td> [@van2006]
</tr> [@johnson2020]
<tr> [@osullivan2019]
<td class="label">Full Name</td> [@takasugi2011]
<td>Sphingosine Kinase 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17q25.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/8877" target="_blank">8877</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000176884" target="_blank">ENSG00000176884</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/603730" target="_blank">603730</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NYA1" target="_blank">Q9NYA1</a></td>
</tr>
<tr>
<td class="label">Protein</td>
<td>[Sphingosine Kinase 1 Protein](/proteins/sphk1-protein)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Multiple Sclerosis</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>[Hippocampus](/brain-regions/hippocampus), [Cortex](/brain-regions/cortex), Cerebellum, White matter (widespread)</td>
</tr>
<tr>
<th class="infobo

...

SPHK1 — Sphingosine Kinase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPHK1 — Sphingosine Kinase 1</th>
</tr>
<tr> [@duran2020]
<td class="label">Symbol</td> [@gulbins2013]
<td><strong>SPHK1</strong></td> [@van2006]
</tr> [@johnson2020]
<tr> [@osullivan2019]
<td class="label">Full Name</td> [@takasugi2011]
<td>Sphingosine Kinase 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17q25.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/8877" target="_blank">8877</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000176884" target="_blank">ENSG00000176884</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/603730" target="_blank">603730</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NYA1" target="_blank">Q9NYA1</a></td>
</tr>
<tr>
<td class="label">Protein</td>
<td>[Sphingosine Kinase 1 Protein](/proteins/sphk1-protein)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Multiple Sclerosis</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>[Hippocampus](/brain-regions/hippocampus), [Cortex](/brain-regions/cortex), Cerebellum, White matter (widespread)</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Pathways</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">Sphingolipid metabolism, S1P signaling, ceramide-S1P rheostat, [NF-κB](/entities/nf-kb), [autophagy](/entities/autophagy) regulation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">145 edges</a></td>
</tr>
</table>

SPHK1 — Sphingosine Kinase 1

Overview

SPHK1 (Sphingosine Kinase 1) encodes a lipid kinase that catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P), a bioactive sphingolipid mediator with critical roles in cell survival, neuroinflammation, and vascular biology. Located on chromosome 17q25.1, SPHK1 is a central regulator of the ceramide-S1P rheostat — the balance between pro-apoptotic ceramide/sphingosine and pro-survival S1P that determines cell fate decisions in [neurons](/entities/neurons) and glia.

In the nervous system, SPHK1-generated S1P signals through five G-protein-coupled receptors (S1PR1-5) to regulate neuronal survival, microglial activation, astrocyte reactivity, oligodendrocyte differentiation, and [blood-brain barrier](/entities/blood-brain-barrier) integrity. Dysregulation of SPHK1 and the sphingolipid rheostat is increasingly recognized as a pathogenic mechanism in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/als), and multiple sclerosis.

Gene Structure

The SPHK1 gene spans approximately 5.5 kb and contains 6 exons. Three major isoforms (SPHK1a, SPHK1b, SPHK1c) are generated by alternative transcription initiation from different 5' exons. SPHK1a (42.5 kDa) is the most abundant isoform in the brain, while SPHK1b has an additional 86 N-terminal amino acids that confer distinct membrane-targeting properties.

Regulatory Elements

[NF-κB](/genes/nfkb1) binding sites: Pro-inflammatory cytokines ([TNF-α](/genes/tnf), [IL-1β](/genes/il1b)) transcriptionally upregulate SPHK1
AP-1 response elements: Growth factor and stress signaling activates SPHK1 transcription through [FOS](/genes/fos)/[JUN](/genes/jun)
ERK1/2-dependent phosphorylation: Post-translational activation at S225 by ERK1/2 promotes membrane translocation
HIF-1α binding sites: Hypoxia induces SPHK1 expression
Epigenetic regulation: SPHK1 promoter methylation status changes with aging and disease

Function

Sphingolipid Rheostat

SPHK1 is the master regulator of the ceramide-S1P balance that controls neuronal fate:

Mermaid diagram (expand to render)

Key Functions in the Nervous System

Neuronal survival signaling: SPHK1-generated S1P activates pro-survival pathways including PI3K/[AKT](/genes/akt1), ERK1/2, and [BCL2](/genes/bcl2) family anti-apoptotic proteins. S1P suppresses ceramide-induced mitochondrial [apoptosis](/entities/apoptosis) by preventing [BAX](/genes/bax) activation and cytochrome c release.

Neuroinflammation regulation: SPHK1 is rapidly upregulated in activated [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes). While acute S1P generation promotes protective inflammatory responses, chronic SPHK1 activation drives pathological neuroinflammation through sustained NF-κB activation and pro-inflammatory cytokine production.

Autophagy modulation: S1P generated by SPHK1 induces autophagy by interacting with [Beclin-1](/genes/becn1) and displacing [BCL2](/genes/bcl2) from the Beclin-1/VPS34 complex. This SPHK1-autophagy axis is critical for clearance of protein aggregates.

Blood-brain barrier maintenance: S1P signaling through S1PR1 on endothelial cells strengthens tight junctions ([CLDN5](/genes/cldn5), [OCLN](/genes/ocln)) and maintains BBB integrity. SPHK1 deficiency increases BBB permeability.

Oligodendrocyte biology: SPHK1 and S1P signaling regulate oligodendrocyte precursor cell survival and differentiation, influencing myelination and remyelination processes.

Calcium homeostasis: Intracellular S1P mobilizes calcium from ER stores independently of IP3 receptors, modulating neuronal excitability and synaptic transmission.

Disease Associations

Alzheimer's Disease

SPHK1 dysfunction is a prominent feature of [AD](/diseases/alzheimers-disease) pathogenesis:

Reduced SPHK1 activity: SPHK1 protein levels and enzymatic activity are significantly decreased in AD hippocampus and cortex, particularly in early Braak stages (I-II), suggesting it is an early pathological event. This shifts the rheostat toward ceramide accumulation and pro-apoptotic signaling.
Ceramide accumulation: With diminished SPHK1 activity, ceramide species (especially C16:0 and C18:0 ceramides) accumulate in AD brain tissue and CSF, promoting neuronal apoptosis and correlating with disease severity.
Aβ-SPHK1 interaction: [Amyloid-β](/proteins/amyloid-beta) oligomers directly inhibit SPHK1 activity, creating a vicious cycle: Aβ reduces S1P → decreased neuroprotection → more neuronal death → more Aβ release.
[Tau](/proteins/tau) phosphorylation: Ceramide accumulation from SPHK1 loss activates [GSK3β](/genes/gsk3b) and [PP2A](/genes/ppp2r1a) dysregulation, promoting [tau](/proteins/tau) hyperphosphorylation.
S1P as biomarker: Reduced S1P levels in CSF and plasma have been proposed as potential AD biomarkers, reflecting decreased SPHK1 activity in the brain.
[BACE1](/entities/bace1) regulation: Ceramide accumulation increases [BACE1](/genes/bace1) stability and activity, enhancing amyloidogenic [APP](/entities/app-protein) processing.

Parkinson's Disease

Glucocerebrosidase connection: SPHK1 interacts with the [GBA1](/genes/gba1)/glucocerebrosidase pathway. GBA1 mutations (the strongest genetic risk factor for PD) disrupt sphingolipid metabolism, and SPHK1 compensation is impaired.
[α-Synuclein](/proteins/alpha-synuclein) aggregation: Ceramide accumulation from SPHK1 reduction promotes α-synuclein oligomerization and impairs autophagic clearance through reduced S1P-Beclin-1 interaction.
Dopaminergic neuron death: SPHK1 is expressed in substantia nigra dopaminergic neurons. Its downregulation sensitizes these neurons to oxidative stress and mitochondrial dysfunction.
Lysosomal dysfunction: S1P regulates lysosomal calcium through TRPML1 channels. SPHK1 deficiency impairs lysosomal function, contributing to the lysosomal storage defect seen in PD.

Multiple Sclerosis

Fingolimod (FTY720): The first oral MS therapy is a sphingosine analog phosphorylated by [SPHK2](/genes/sphk2) to produce FTY720-P, which acts as a functional S1PR antagonist. This demonstrates the therapeutic potential of targeting S1P signaling.
Demyelination: Altered SPHK1/ceramide balance in oligodendrocytes contributes to demyelination. S1P promotes oligodendrocyte survival and remyelination.
Immune cell trafficking: S1P gradients (maintained by SPHK1) control lymphocyte egress from lymph nodes, directly relevant to MS pathogenesis.

ALS

Motor neuron vulnerability: SPHK1 is downregulated in spinal motor neurons in ALS, contributing to increased ceramide-mediated apoptosis.
Glial activation: Aberrant SPHK1 activation in reactive [astrocytes](/entities/astrocytes) promotes inflammatory S1P secretion that may damage motor neurons.

Expression Pattern

Hippocampus: Strong expression in pyramidal neurons; significantly reduced in AD
Cortex: Moderate expression across all layers; decreased in temporal and frontal lobes in AD
Cerebellum: Expression in Purkinje cells and granule cells
Substantia nigra: Moderate expression in dopaminergic neurons
White matter: Expressed in oligodendrocytes, important for myelin maintenance
[Microglia](/cell-types/microglia): Low basal expression; dramatically upregulated upon activation
[Astrocytes](/cell-types/astrocytes): Moderate expression; increases with reactive astrogliosis
Vascular endothelium: High expression, maintains BBB S1P gradient

Therapeutic Implications

SPHK1 Activation Strategies

SPHK1 activators: Small molecule activators of SPHK1 (e.g., K6PC-5) shift the rheostat toward S1P, showing neuroprotective effects in AD models by reducing ceramide-mediated apoptosis and enhancing autophagy.

S1P receptor agonists: Selective S1PR1 agonists (ozanimod, siponimod) are approved for MS and may have broader neuroprotective potential through direct CNS effects.

Ceramidase enhancers: Increasing acid ceramidase activity reduces ceramide accumulation and generates sphingosine substrate for SPHK1.

Gene therapy: AAV-mediated SPHK1 overexpression in hippocampus has shown protection against Aβ toxicity in mouse models.

Targeting the Sphingolipid Rheostat

Ceramide synthase inhibitors: Fumonisin B1 and selective CERS inhibitors reduce toxic ceramide accumulation
Sphingomyelinase inhibitors: Blocking acid sphingomyelinase (ASM) reduces ceramide production from sphingomyelin
S1P lyase inhibitors: Preventing S1P degradation maintains protective S1P levels

Key Publications

[Ceccom et al., Reduced sphingosine kinase-1 and S1P in Alzheimer's disease brain (2012)](https://doi.org/10.1016/j.neurobiolaging.2011.05.009)

[Hagen et al., Sphingosine-1-phosphate and the ceramide-S1P rheostat in neurodegeneration (2011)](https://doi.org/10.1016/j.bbalip.2011.06.004)

[Maceyka et al., Sphingosine-1-phosphate signaling and its role in disease (2012)](https://doi.org/10.1016/j.tips.2012.03.002)

[Couttas et al., Loss of the sphingolipid S1P in Alzheimer's brain linked to cerebrovascular disease (2014)](https://doi.org/10.1007/s00401-014-1305-1)

[Pitson, Regulation of sphingosine kinase and sphingolipid signaling (2011)](https://doi.org/10.1016/j.tibs.2010.09.003)

[Brinkmann et al., Fingolimod (FTY720): discovery and development (2010)](https://doi.org/10.1038/nrd3048)

[He et al., Sphingosine kinase 1 deficiency exacerbates α-synuclein accumulation in PD (2019)](https://doi.org/10.1016/j.nbd.2019.104487)

[van Echten-Deckert & Alam, Sphingolipid metabolism in neural cells (2023)](https://doi.org/10.1016/j.bbalip.2022.159260)

[Grassi et al., Sphingolipids and neurodegeneration: mechanisms and therapeutic potential (2019)](https://doi.org/10.1007/978-3-030-12668-1_4)

[Takasugi et al., BACE1 activity is modulated by cell-associated sphingosine-1-phosphate (2011)](https://doi.org/10.1523/JNEUROSCI.0519-11.2011)

External Links

[NCBI Gene: sphk1](https://www.ncbi.nlm.nih.gov/gene/)
[PubMed: sphk1](https://pubmed.ncbi.nlm.nih.gov/?term=sphk1+neurodegeneration)

References

[Unknown, Pyne & Pyne, Sphingosine 1-phosphate and cancer (2020) (2020)](https://doi.org/10.1016/j.tcb.2020.04.006)

[Hait et al., Sphingosine kinase 1 in tumor growth and angiogenesis (2009) (2009)](https://doi.org/10.1158/0008-5472.CAN-08-2082)

[Unknown, Merrill, Ceramide and sphingosine metabolism in neurodegenerative diseases (2011) (2011)](https://doi.org/10.1111/j.1471-4159.2011.07251.x)

[He et al., SPHK1 promotes amyloid-β production via autophagy inhibition (2019) (2019)](https://doi.org/10.1038/s41419-019-1594-1)

[Duran et al., Lysosomal ceramide drives non-apoptotic cell death (2020) (2020)](https://doi.org/10.1038/s41467-020-15219-5)

[Gulbins et al., Acid sphingomyelinase and its role in brain diseases (2013) (2013)](https://doi.org/10.1007/s00401-013-1111-z)

[Unknown, van Echten-Deckert & Herget, Sphingolipid metabolism in the CNS (2006) (2006)](https://doi.org/10.1196/annals.1370.005)

[Johnson et al., Targeting sphingosine-1-phosphate signaling in CNS disorders (2020) (2020)](https://doi.org/10.1016/j.pharmthera.2020.107532)

[Unknown, O'Sullivan & Dev, Sphingosine 1-phosphate in neural development (2019) (2019)](https://doi.org/10.1016/j.tins.2019.03.008)

[Takasugi et al., BACE1 activity is modulated by cell-associated sphingosine-1-phosphate (2011) (2011)](https://doi.org/10.1523/JNEUROSCI.0519-11.2011)

Pathway Diagram

The following diagram shows the key molecular relationships involving SPHK1 — Sphingosine Kinase 1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SPHK1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-sphk1
kg_node_id	SPHK1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-552bb2bf19d1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-sphk1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

40%

Debates

0

Incoming

8

Outgoing

35

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SPHK1 — Sphingosine Kinase 1

SPHK1 — Sphingosine Kinase 1

SPHK1 — Sphingosine Kinase 1

SPHK1 — Sphingosine Kinase 1

Overview

Gene Structure

Regulatory Elements

Function

Sphingolipid Rheostat

Key Functions in the Nervous System

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

ALS

Expression Pattern

Therapeutic Implications

SPHK1 Activation Strategies

Targeting the Sphingolipid Rheostat

Key Publications

See Also

External Links

References

Pathway Diagram

💬 Discussion